FDA investigates risk of secondary lymphomas after CAR-T immunotherapy
Bryant Furlow
Topics & Concepts
Chimeric antigen receptorFood and drug administrationImmunotherapyMedicineAgency (philosophy)LymphomaT cellImmunologyOncologyCancer researchPharmacologyImmune systemSociologySocial scienceCAR-T cell therapy research